Actually I believe fair to be closer to $176 - $190 based on my rigorous fundamental and technical analysis and through speaking to industry professionals
- Forums
- ASX - By Stock
- CMS Proposes Major Increase in Reimbursement for Canaloplasty
Actually I believe fair to be closer to $176 - $190 based on my...
-
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
|
|||||
Last
21.5¢ |
Change
-0.005(2.27%) |
Mkt cap ! $50.39M |
Open | High | Low | Value | Volume |
22.5¢ | 22.5¢ | 21.5¢ | $27.83K | 127.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 56700 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.0¢ | 38448 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 82400 | 0.215 |
9 | 390311 | 0.210 |
5 | 113536 | 0.205 |
14 | 180879 | 0.200 |
2 | 20000 | 0.195 |
Price($) | Vol. | No. |
---|---|---|
0.220 | 28955 | 2 |
0.225 | 31400 | 2 |
0.235 | 36964 | 2 |
0.240 | 50000 | 1 |
0.250 | 200000 | 3 |
Last trade - 12.47pm 13/08/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online